Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst

Alzheimer's test

Last week, HC Wainwright hosted Voyager Therapeutics, Inc.’s (NASDAQ:VYGR) management during HCW's Annual Global Investment Conference.

The management emphasized recent preclinical murine data from a head-to-head study showing that its alkaline phosphatase (ALPL) receptor-mediated non-viral NeuroShuttle sustained central nervous system (CNS) exposure for more than 3 weeks compared to less than 1 week with transferrin receptor shuttles, highlighting durability and a potential safety advantage.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.